CALABASAS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") for the purchase and sale of up to 2,222,222 shares of common stock and five-year warrants to purchase up to 2,222,222 shares of common stock at a per share exercise price of $9.00 at a combined purchase price of $7.20, that is expected to result in gross proceeds of up to approximately $16 million to the Company. NeOnc currently intends to use the net proceeds from the offering for repayment of indebtedness, and for working capital and corporate purposes.

The PIPE is led by a $10 million investment by Cinctive Capital Management LP, a multi-strategy investment firm with a focus on biotechnology and therapeutics. The transaction represents a significant vote of confidence from the firm's leadership, particularly Co-Founder and Co-Chief Investment Officer Rich Schimel. Building on this institutional endorsement, Cinctive's leadership further underscores the strength of the investment.

Amir F. Heshmatpour, Executive Chairman, President & CEO of NeOnc Technologies Holdings, Inc., stated: "This strategic investment from a firm of Cinctive Capital's caliber validates our technological approach and the potential of our clinical assets. Rich's track record in identifying high-value opportunities is well recognized. We believe this capital will be instrumental as we accelerate our clinical trials and continue to develop therapies designed to bypass the blood-brain barrier."

Rich Schimel, Co-Founder and Co-Chief Investment Officer of Cinctive Capital Management LP, commented: "We see tremendous potential in NeOnc's proprietary delivery platforms. Our firm seeks opportunities in small-to-mid-cap biotech companies ...